ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2022
Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Evaluation of Volumetric Reference Ranges for SPECT MPI Parameters and the Predictive Power of Dyssynchrony Parameters: A Cross-Sectional StudyCurrent medical imaging · 2026Article
- Prediction of Radiation Therapy Induced Cardiovascular Toxicity from Pretreatment CT Images in Patients with Thoracic Malignancy via an Optimal Biomarker Approach.Academic radiology · 2025Article
- Cardiotoxicity detection tool for breast cancer chemotherapy: a retrospective study.PeerJ. Computer science · 2024Article
- Early prediction of chemotherapy-induced cardiotoxicity.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- Review
- Beta-blockers and mechanical dyssynchrony in heart failure assessed by radionuclide ventriculography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Towards pre-treatment imaging prediction of chemotherapy-related cardiotoxicity.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.
methodsIn this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.
resultsOf the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.
conclusionsThe results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.